Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Proposed regs to set a per diem fee schedule for the ancillary services associated with home I.V. drug delivery under the Medicare outpatient drug program should be ready by the Spring of 1989, according to HCFA Office of Reimbursement Director Charles Booth. Booth told a Sept. 15 conference on Medicare coverage and reimbursement that the Health Care Financing Administration will have to try to have the proposed regs out early next year if the final rules are to be ready by the Fall of next year. That deadline is necessary so that HCFA can have the benefit ready to start by Jan. 1990, as specified by the Catastrophic Care Act. "There are a number of considerations that we will have to make in order to set up this fee schedule," Booth observed. One of the key questions,he said, will be the level of training a person needs to administer the therapy. Another issue will be the length of therapy. Transportation costs, supplies, inventory and overhead will also need to be addressed. HCFA is also prepared to look into safety needs, such as special preparation, handling and disposal of cytotoxins. Booth said HCFA expects there "will be significant comments regardless of what we come up with." He said that the "rulemaking process will be very important for this particular benefit."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts